Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study. Wolf C, Sidhu J, Otoul C, Morris DL, Cnops J, Taubel J, Bennett B PLoS One. 2013; 8(3):e58438. Epub 2013 Mar 05. PMID: 23472197. Abstract CommentRecommendBookmarkWatch